Eduovisual
Cardiovascular
Hyperlipidemia: ASCVD risk estimation and primary-prevention statin initiation
— Hyperlipidemia = elevated total cholesterol, LDL-C, non-HDL-C, or triglycerides; the primary-prevention question is who benefits from a statin before any ASCVD event occurs
— ASCVD = clinical atherosclerotic disease: acute coronary syndrome, MI, stable/unstable angina, coronary or arterial revascularization, stroke/TIA of atherosclerotic origin, peripheral arterial disease
— Universal lipid screening in adults: USPSTF supports statin use in adults 40–75 with ≥1 ASCVD risk factor and 10-yr ASCVD risk ≥10% (Grade B); ACC/AHA recommends screening starting at age 20 with a fasting or non-fasting lipid panel
— Repeat every 4–6 years in low-risk adults; more often if borderline/intermediate risk or risk factors evolve
— Universal pediatric screening once between ages 9–11 and again 17–21 (NHLBI) — flag familial hypercholesterolemia (FH)
— Family history of premature ASCVD (male <55, female <65 in first-degree relative)
— LDL-C ≥190 mg/dL → presume familial hypercholesterolemia until proven otherwise
— Tendon xanthomas, xanthelasma in a young patient, corneal arcus <45 yo
— Pancreatitis with TG >500 mg/dL
— Comorbid conditions that magnify risk: DM, CKD (eGFR 15–59), HIV, chronic inflammatory disease (RA, psoriasis, lupus), preeclampsia/early menopause
— The exam tests the decision to start a statin, not memorizing lipid cut-offs; you must integrate pooled cohort equation (PCE) 10-yr ASCVD risk with risk-enhancing features and patient preference
— Outpatient/ambulatory voice: shared decision-making visit, counseling, lifestyle, then medication
Board pearl: Any adult 20–75 with LDL-C ≥190 mg/dL gets a high-intensity statin regardless of calculated risk — no PCE needed.
— Primary-prevention hyperlipidemia is almost always discovered on routine screening; the "presentation" is a lipid panel, not a symptom
— Step 3 stems open with "a 52-year-old comes for a routine visit" — your job is risk estimation, not chasing chest pain
— Age and sex (PCE inputs): equation validated for ages 40–79; output drives statin intensity
— Race/ethnicity: PCE was derived in non-Hispanic Black and White cohorts; overestimates risk in South Asian, East Asian populations — adjust with risk-enhancers and coronary artery calcium (CAC)
— Tobacco: current smoker is a PCE input AND a risk-enhancer; quantify pack-years
— Hypertension: treated vs untreated, current SBP
— Diabetes: type, duration ≥10 yr (T2DM) or ≥20 yr (T1DM), albuminuria, retinopathy, neuropathy, ABI <0.9 — all are diabetes-specific risk enhancers
— Family history of premature ASCVD
— Chronic inflammatory conditions: RA, psoriasis, lupus, HIV
— Pregnancy history: preeclampsia, gestational diabetes, premature menopause (<40), early menarche
— Lifestyle: diet (saturated fat, processed carbs), exercise minutes/week, alcohol, sleep apnea
— Thiazides, atypical antipsychotics, protease inhibitors, glucocorticoids, cyclosporine, retinoids, second-gen β-blockers
— Estrogen replacement raises TG
— Cold intolerance, weight gain, fatigue → hypothyroidism (TSH before/with statin if any clue)
— Polyuria/polydipsia → uncontrolled DM
— Claudication, exertional chest discomfort, TIA-like spells → reclassify as secondary prevention
Key distinction: Once a patient has clinical ASCVD, you skip the PCE entirely — they move to the secondary-prevention algorithm with high-intensity statin ± non-statin add-ons.
— BMI, waist circumference (≥40 in men, ≥35 in women = metabolic syndrome criterion)
— Resting BP both arms; orthostatics if elderly or symptomatic
— Resting HR (high HR can be a marker of deconditioning or hyperthyroidism)
— Tendon xanthomas (Achilles, extensor tendons of hands) → classic for heterozygous FH
— Xanthelasma (yellow plaques on eyelids) — may be normolipemic but should prompt panel
— Corneal arcus under age 45 → suggests FH
— Eruptive xanthomas (yellow papules on buttocks, extensor surfaces) → marked hypertriglyceridemia (TG often >1000), pancreatitis risk
— Palmar xanthomas (orange-yellow streaks in palmar creases) → dysbetalipoproteinemia (type III, ApoE2/E2)
— Lipemia retinalis on fundoscopy with severe hypertriglyceridemia
— Carotid bruits
— Femoral, popliteal, dorsalis pedis, posterior tibial pulses; ankle-brachial index if claudication, non-healing ulcer, diminished pulses, or age >65 with risk factors
— Abdominal aortic palpation; one-time AAA ultrasound in men 65–75 who ever smoked
— Skin changes of chronic PAD (hair loss, shiny skin, dependent rubor)
— S4 (LV stiffness from HTN), displaced PMI (LVH), murmurs (AS can mimic angina later)
— Goiter, delayed reflexes, dry skin → hypothyroidism
— Cushingoid features → glucocorticoid effect
— Acanthosis nigricans → insulin resistance
Board pearl: Tendon xanthomas + LDL ≥190 + premature CAD family history in a young adult = familial hypercholesterolemia — cascade-screen first-degree relatives and start high-intensity statin immediately, even before PCE.
— Total cholesterol, HDL-C, triglycerides; LDL-C calculated via Friedewald (LDL = TC − HDL − TG/5) when TG <400 mg/dL
— Non-HDL-C (= TC − HDL) is reliable regardless of fasting status and when TG are high; goal often used in DM/metabolic syndrome
— Fasting vs non-fasting: 2018 ACC/AHA and ESC accept non-fasting for routine screening; fast 8–12 h if TG >400 or if calculating LDL with high TG
— Repeat abnormal panel at least once before committing to lifelong therapy (biologic variability ~10%)
— LDL ≥190 mg/dL → repeat to confirm, then treat as FH; consider genetic testing in select patients
— ALT/AST — baseline; routine periodic monitoring is no longer required unless symptoms
— CK — only if patient has muscle symptoms or is high-risk (elderly, CKD, hypothyroidism, drug interactions); not a universal baseline anymore
— TSH — rule out hypothyroidism (treat hypothyroidism first; can normalize LDL)
— Fasting glucose or HbA1c — diabetes screening and to capture statin-associated new-onset DM risk
— Basic metabolic panel — eGFR for CKD (CKD is a risk-enhancer)
— Urine albumin-to-creatinine ratio in diabetics
— Hypothyroidism, nephrotic syndrome (urinalysis), cholestatic liver disease (alk phos, bilirubin), uncontrolled DM, anorexia, pregnancy, obstructive liver disease, chronic alcohol, drugs
— Pooled Cohort Equation (PCE) for ages 40–79; output = 10-yr ASCVD risk %
— PREVENT (AHA 2023) — newer 10- and 30-yr equation including kidney/metabolic measures; increasingly referenced
Step 3 management: When you see TG >500 mg/dL, your first move is to lower TG to prevent pancreatitis (fibrate, fish oil, glycemic control, alcohol cessation) — not to chase LDL.
— Indication: borderline (5–<7.5%) or intermediate (7.5–<20%) 10-yr ASCVD risk where the statin decision is uncertain after shared decision-making
— Non-contrast cardiac CT, low radiation, no IV contrast
— Interpretation
— CAC = 0 → very low event rate; reasonable to defer statin for 5–10 years, except in current smokers, diabetics, strong family history, or LDL ≥190
— CAC 1–99 → favor statin, especially age ≥55
— CAC ≥100 or ≥75th percentile for age/sex/race → initiate statin regardless of calculated PCE risk
— Family history premature ASCVD
— Persistent LDL-C ≥160 or non-HDL ≥190
— CKD (eGFR 15–59)
— Metabolic syndrome
— Chronic inflammatory disease (RA, psoriasis, HIV, lupus)
— Preeclampsia, premature menopause (<40)
— South Asian ancestry
— Persistently elevated hs-CRP ≥2 mg/L, Lp(a) ≥50 mg/dL or ≥125 nmol/L, ApoB ≥130 mg/dL, or ABI <0.9
— Check once in lifetime, especially with premature ASCVD, FH, or strong family history
— Genetically determined; elevated Lp(a) is an independent ASCVD risk factor and a risk-enhancer
— Better residual-risk markers in metabolic syndrome, DM, and hypertriglyceridemia than LDL alone
— Already on statin (won't change management)
— Known ASCVD (already secondary prevention)
— Very low risk (<5%) or very high risk (≥20%) — decision is already made
Board pearl: A 55-year-old with 10-yr ASCVD risk of 12% who is statin-hesitant → order CAC; CAC = 0 justifies deferring; CAC ≥100 clinches the prescription.
1. Clinical ASCVD → high-intensity statin (secondary prevention, separate algorithm)
2. LDL-C ≥190 mg/dL, age ≥20 → high-intensity statin; no risk calculation needed
3. Diabetes, age 40–75, LDL 70–189 → at least moderate-intensity statin; high-intensity if multiple DM-specific risk-enhancers or 10-yr risk ≥20%
4. Age 40–75, LDL 70–189, no DM, no ASCVD → use PCE to estimate 10-yr ASCVD risk
— <5% (low): emphasize lifestyle; reassess in 4–6 years
— 5 – <7.5% (borderline): lifestyle; consider moderate-intensity statin if risk enhancers present
— 7.5 – <20% (intermediate): shared decision-making; moderate-intensity statin recommended; high-intensity if risk-enhancers; CAC can refine
— ≥20% (high): high-intensity statin, aim for ≥50% LDL reduction
— High-intensity (≥50% LDL reduction): atorvastatin 40–80, rosuvastatin 20–40
— Moderate-intensity (30–49% LDL reduction): atorvastatin 10–20, rosuvastatin 5–10, simvastatin 20–40, pravastatin 40, lovastatin 40
— Low-intensity (<30%): only when patient cannot tolerate higher doses
— Age 20–39 without LDL ≥190: focus on lifestyle; statin only with FH or strong family history of premature ASCVD
— Age 76–79: PCE still applies; data weaker but reasonable
— Age ≥75 primary prevention: shared decision-making; consider life expectancy, frailty, polypharmacy; statins not contraindicated but evidence is limited
Step 3 management: Always document shared decision-making before starting a statin in primary prevention — the exam loves the answer "discuss risks and benefits, then initiate statin."
— Mechanism: HMG-CoA reductase inhibition → upregulates hepatic LDL receptors → lowers LDL-C; also stabilizes plaque, reduces inflammation (pleiotropic)
— Atorvastatin and rosuvastatin are workhorses — long half-life, dose any time of day, fewer drug interactions than simvastatin
— Pravastatin and rosuvastatin are minimally metabolized by CYP3A4 → preferred with HIV protease inhibitors, cyclosporine, certain antifungals, macrolides
— Simvastatin has the most interactions; avoid with amiodarone (max 20 mg), amlodipine (max 20 mg), and never combine with gemfibrozil
— Start at the intensity you need; uptitrate at 4–12 weeks based on LDL response
— Take simvastatin and lovastatin in the evening (short half-life, hepatic synthesis peaks at night)
— Atorvastatin/rosuvastatin any time
— Fasting lipid panel 4–12 weeks after start or dose change, then every 3–12 months
— Goal: confirm expected LDL reduction (≥30% moderate, ≥50% high intensity)
— Routine ALT/CK monitoring not required; check if symptoms (muscle pain, dark urine, jaundice)
— Statin-associated muscle symptoms (SAMS): 5–10% report; true myopathy with CK elevation is rare
— Strategy: hold statin → re-challenge with same or different statin at lower dose → try rosuvastatin or pravastatin twice weekly
— Check TSH, vitamin D, and review interacting drugs before labeling true intolerance
— New-onset DM: small absolute risk increase (~0.1%/yr), but ASCVD benefit far outweighs; do not stop the statin — manage glucose
— Transaminitis: mild ALT bumps common; stop only if >3× ULN with symptoms
— Rhabdomyolysis: rare; CK >10× ULN with myoglobinuria — stop, hydrate
— Active liver disease, pregnancy/lactation (statins remain Category X by tradition; ACOG now permits in selected high-risk patients but exam answer is stop in pregnancy)
Board pearl: A patient on atorvastatin develops bilateral thigh ache with normal CK and normal TSH — hold for 2–4 weeks; if symptoms resolve, re-challenge with rosuvastatin low-dose before declaring statin intolerance.
— LDL ≥190 / FH: if on maximally tolerated statin and LDL still ≥100, add ezetimibe; if still inadequate or very high risk, add PCSK9 inhibitor (evolocumab, alirocumab)
— Diabetes with multiple risk-enhancers: add ezetimibe if LDL remains ≥70 on high-intensity statin (more typical in secondary prevention but acceptable here)
— Statin intolerance: ezetimibe ± bempedoic acid (CLEAR Outcomes showed ASCVD benefit in statin-intolerant patients); bile-acid sequestrants if needed
— Inhibits intestinal NPC1L1 cholesterol absorption; lowers LDL ~18–25%
— Well tolerated; no CYP interactions; safe in CKD
— SC injection q2 weeks; lowers LDL ~50–60% on top of statin
— Reserved for FH or very-high-risk patients not at goal
— Inclisiran (siRNA) — twice yearly SC after loading
— ATP-citrate lyase inhibitor; lowers LDL ~15–25%; can raise uric acid and tendon rupture risk
— Can raise TG; avoid if TG >300; colesevelam can lower A1c in DM
— First: treat underlying cause — uncontrolled DM, alcohol, hypothyroidism, drugs (estrogen, thiazides, retinoids)
— Lifestyle: very-low-fat diet, abstain from alcohol, weight loss, exercise
— Pharm: fibrate (fenofibrate preferred — gemfibrozil + statin = ↑rhabdo); omega-3 fatty acids 2–4 g/day
— Icosapent ethyl (Vascepa) — purified EPA — adds ASCVD benefit when TG 135–499 in high-risk patients already on statin (REDUCE-IT); mixed EPA/DHA preparations did not show benefit
Key distinction: Statin + gemfibrozil = high rhabdomyolysis risk → use fenofibrate when combining; never combine gemfibrozil with statins on the exam.
— PCE technically validated to 79; statins reasonable, especially with risk-enhancers or CAC ≥100
— Consider competing risks, life expectancy, polypharmacy
— USPSTF: insufficient evidence to recommend for or against initiating; individualize
— Use shared decision-making; if frail, life expectancy <5–10 years, advanced dementia — usually defer
— Do not stop a tolerated statin in someone who was already on it just because they crossed 75
— Prefer moderate-intensity at initiation; watch for drug interactions (polypharmacy, CYP3A4)
— CKD (eGFR 15–59) is itself a risk-enhancer; favor statin in primary prevention
— Dose caps: rosuvastatin max 10 mg/day if eGFR <30 (not on dialysis); simvastatin max 40 mg
— Atorvastatin does not require renal dose adjustment — often the easiest choice in CKD
— Dialysis-dependent ESRD: do not initiate a statin for primary prevention (no benefit shown — 4D, AURORA); continue if already on for secondary prevention
— Post-renal transplant: statins are indicated; watch interactions with cyclosporine/tacrolimus (use pravastatin, fluvastatin, low-dose rosuvastatin)
— Active liver disease or unexplained persistent transaminase elevation >3× ULN → contraindication
— NAFLD/NASH is not a contraindication — statins are safe and often beneficial
— Compensated cirrhosis (Child-Pugh A): cautious use, low-dose
— Decompensated cirrhosis (Child-Pugh B/C): avoid
— Amiodarone + simvastatin >20 mg → myopathy
— Diltiazem/verapamil + simvastatin/lovastatin → myopathy
— Clarithromycin/erythromycin + atorvastatin/simvastatin → hold statin during course
— Grapefruit juice (>1 L/day) inhibits CYP3A4
Step 3 management: A 70-year-old with eGFR 25 on rosuvastatin 40 mg → reduce to 10 mg or switch to atorvastatin; this is a frequent CCS/MCQ pitfall.
— Cholesterol physiologically rises in pregnancy; do not screen routinely
— Statins: traditionally contraindicated (Category X historically); FDA removed the strict contraindication in 2021 because data do not show consistent teratogenicity, but standard exam answer is to discontinue statins before conception or upon discovery of pregnancy
— Exception: very high-risk women (homozygous FH, prior ASCVD) may continue under specialist guidance
— Bile-acid sequestrants (colesevelam) are the safest agents in pregnancy if pharmacotherapy is required
— Fibrates, ezetimibe, niacin, PCSK9 inhibitors — avoid; insufficient data
— Lactation: statins generally avoided; pravastatin sometimes used if essential
— Women of childbearing potential on statins: discuss contraception; stop statin 1–3 months before planned conception
— Universal lipid screening once between ages 9–11 and again 17–21 (NHLBI/AAP)
— Selective screening earlier (age 2–8) with family history of premature ASCVD or FH
— Familial hypercholesterolemia:
— Heterozygous FH (1:250) → start statin at age 8–10 if LDL ≥190, or ≥160 with family history; goal LDL <130 or ≥50% reduction
— Homozygous FH (1:300,000) → tendon xanthomas as child, cardiac events in teens; statin + ezetimibe + PCSK9 + LDL apheresis
— Lifestyle is foundational at every age
— South Asian ancestry: risk-enhancer; PCE underestimates → lower threshold for statin or order CAC
— East Asian: PCE may overestimate; CAC helpful; statin dose response often higher (use lower starting doses of rosuvastatin per FDA labeling — max 20 mg in Asian patients per package insert)
— Black patients: well-represented in PCE; same thresholds apply
— Risk-enhancer; prefer pravastatin, rosuvastatin, pitavastatin (fewer PI interactions); REPRIEVE trial supports pitavastatin in primary prevention with low-to-moderate ASCVD risk
Board pearl: A 9-year-old girl has LDL 245 and a father who had MI at 38 — diagnose heterozygous FH, cascade-screen the family, initiate a pediatric-dose statin, refer to lipid specialist.
— Atherosclerotic cardiovascular disease: MI, stable/unstable angina, ischemic stroke, TIA, peripheral arterial disease, mesenteric ischemia, renovascular disease, abdominal aortic aneurysm
— Pancreatitis when TG >1000 mg/dL (and increasingly with TG 500–1000)
— Eruptive xanthomas, lipemia retinalis with severe hypertriglyceridemia
— Familial hypercholesterolemia: untreated heterozygous FH → MI by age 50 in men, 60 in women; homozygous FH → events in childhood
— SAMS — myalgia without CK rise (most common), myopathy with CK 3–10× ULN, severe myopathy >10× ULN, rhabdomyolysis with renal injury (rare, <0.1%)
— Higher risk: elderly, female, low BMI, hypothyroidism, CKD, vitamin D deficiency, Asian ancestry, drug interactions, high-intensity dosing
— Hepatotoxicity: mild transaminitis common; clinically significant liver injury <1%
— New-onset diabetes mellitus: NNH ~255 over 4 years vs NNT ~155 for major vascular events — net benefit favors statin
— Cognitive complaints: case reports of memory issues; large trials and meta-analyses do not confirm a true association; counsel reassuringly
— Hemorrhagic stroke: small absolute increase in patients with prior hemorrhagic stroke; not relevant to most primary-prevention patients
— Recognize: muscle pain + weakness + dark urine + CK >10× ULN
— Management: stop statin, IV fluids, monitor renal function and potassium, treat hyperkalemia, identify precipitant (new CYP3A4 inhibitor, AKI)
— ~50% discontinue statins within 1 year — a major patient-safety and outcomes issue; address proactively
Key distinction: Myalgia with normal CK is not myopathy — re-challenge after a washout; rhabdomyolysis (CK >10×, myoglobinuria, AKI) means permanent discontinuation of that agent.
— Suspected or confirmed familial hypercholesterolemia (LDL ≥190, tendon xanthomas, premature ASCVD family history)
— Homozygous FH — apheresis, lomitapide, evinacumab, evolocumab
— LDL not at goal on maximally tolerated statin + ezetimibe (PCSK9 inhibitor candidacy)
— Severe statin intolerance with multiple failed re-challenges
— Persistent TG >500 mg/dL despite first-line therapy
— Elevated Lp(a) with strong family history or premature events
— Complex secondary causes (genetic dyslipidemias, organ transplant patients)
— Coexisting uncontrolled DM, thyroid disease, suspected lipodystrophy or Cushing syndrome
— Acute pancreatitis from hypertriglyceridemia (TG usually >1000)
— Admit; IV fluids, NPO, analgesia; insulin infusion (activates lipoprotein lipase, lowers TG) ± apheresis if severe
— Once stable, transition to PO fibrate + omega-3 + tight glycemic control
— Rhabdomyolysis from statin
— Admit for IV hydration, monitor K+, Cr, urine output; nephrology if AKI
— Severe statin hepatotoxicity with jaundice or coagulopathy
— Chest pain → ED for ACS workup; once diagnosed, patient moves to secondary-prevention algorithm, high-intensity statin in hospital
— Stroke/TIA → stroke unit; statin started inpatient
— Outpatient discovery of LDL 240 → counsel → diet/exercise → atorvastatin 40 mg → recheck lipids 4–12 weeks → uptitrate or add ezetimibe → if FH suspected, refer to lipid clinic and order cascade screening
CCS pearl: Severe hypertriglyceridemic pancreatitis — order IV insulin infusion + IV dextrose to maintain euglycemia; this is faster and cheaper than apheresis and is the high-yield CCS move.
— Treating the cause may normalize lipids and avoid lifelong therapy
— Hypothyroidism — raises LDL and TG via ↓LDL receptor expression; check TSH in every new dyslipidemia patient; treating hypothyroidism can drop LDL 30%
— Diabetes mellitus (especially T2DM, poor control) — high TG, low HDL, small dense LDL; manage glucose first/alongside
— Cushing syndrome / chronic glucocorticoids — ↑LDL, ↑TG
— Polycystic ovary syndrome — atherogenic dyslipidemia pattern
— Nephrotic syndrome — markedly elevated LDL and TC due to hepatic compensatory synthesis (urinalysis for proteinuria mandatory)
— Chronic kidney disease — ↑TG, ↓HDL, lipoprotein abnormalities
— Cholestatic liver disease (PBC, biliary obstruction) — ↑TC with lipoprotein X
— NAFLD — atherogenic pattern
— Thiazide diuretics, second-gen β-blockers (atenolol, metoprolol IR), atypical antipsychotics (olanzapine, clozapine), protease inhibitors, glucocorticoids, cyclosporine/tacrolimus, retinoids (isotretinoin), oral estrogens, tamoxifen
— Excess alcohol → TG ↑↑
— High refined carbohydrate intake → TG ↑
— Anorexia nervosa → paradoxical ↑LDL
— Pregnancy → physiologic ↑ in all lipid fractions
— Heterozygous FH (LDLR, ApoB, PCSK9): LDL 200–400, tendon xanthomas, premature CAD
— Homozygous FH: LDL >500, childhood xanthomas, MI in adolescence
— Familial combined hyperlipidemia: variable ↑LDL and ↑TG, very common
— Familial hypertriglyceridemia: TG 250–1000
— Familial chylomicronemia / lipoprotein lipase deficiency: TG often >1000, eruptive xanthomas, pancreatitis
— Dysbetalipoproteinemia (type III, ApoE2/E2): palmar xanthomas, equally ↑TC and ↑TG
Board pearl: Any patient with new LDL >250 — order TSH, urinalysis (or UACR), HbA1c, and LFTs before initiating a statin.
— Inflammatory arthritis (RA, psoriatic arthritis, lupus): elevated ASCVD risk independent of lipid level; control inflammation and treat lipids — a risk-enhancer not captured by PCE
— HIV: chronic inflammation + protease inhibitor effects; risk-enhancer
— Chronic kidney disease: not in PCE; risk-enhancer
— Post-transplant: solid-organ transplant patients carry elevated ASCVD risk independent of lipids
— Survivors of pediatric/adolescent cancer treated with chest radiation or anthracyclines
— Hypothyroidism — proximal myopathy, ↑CK; check TSH before declaring statin myopathy
— Vitamin D deficiency — myalgia
— Polymyalgia rheumatica — elderly, ↑ESR, shoulder/hip girdle pain
— Inflammatory myopathies (polymyositis, immune-mediated necrotizing myopathy — anti-HMGCR antibodies can be triggered by statins and persist after withdrawal)
— Hereditary muscle disease (McArdle, mitochondrial)
— Recent strenuous exercise; trauma
— Lipoprotein(a) elevation — counted within LDL-C on standard panels; consider when LDL is "high" but ApoB and non-HDL look better
— Lipoprotein X in cholestasis — falsely elevated LDL
— Hypertension (treat in parallel)
— Smoking (cessation reduces risk faster than statins)
— Obesity, sedentary lifestyle, diet
— Sleep apnea, periodontal disease, depression — emerging associations
— Non-adherence is the #1 reason LDL fails to drop; verify pill counts, pharmacy refills
— Drug interactions reducing statin levels (rifampin, St. John's wort)
— Wrong test timing or non-fasting with high TG distorting calculated LDL
Key distinction: Statin myopathy with persistent CK elevation off the drug for >2 months + proximal weakness → consider anti-HMGCR immune-mediated necrotizing myopathy — refer to rheumatology, not a simple re-challenge.
— Diet: Mediterranean or DASH pattern preferred; ↓saturated fat (<6% of calories), ↓trans fat (none), ↑fiber, ↑plant sterols, ↑fatty fish; PREDIMED showed Mediterranean diet reduces ASCVD events
— Physical activity: ≥150 min/week moderate or ≥75 min/week vigorous aerobic + 2 sessions resistance training
— Weight: 5–10% loss improves lipids, BP, glucose
— Tobacco cessation: single most effective ASCVD intervention; offer pharmacotherapy (varenicline, bupropion, NRT) + counseling at every visit
— Alcohol moderation: ≤1 drink/day women, ≤2 men; less if hypertriglyceridemia
— Sleep: 7–9 hours; treat OSA
— Hypertension: target <130/80 in most adults with elevated ASCVD risk
— Diabetes: A1c individualized (~<7%); use SGLT2 inhibitors and GLP-1 receptor agonists for ASCVD/HF/CKD benefit when indicated
— Aspirin in primary prevention: USPSTF 2022 — selective use ages 40–59 with 10-yr ASCVD ≥10% (individualized); no longer routinely recommended ≥60; bleeding risk often outweighs benefit
— Annual influenza vaccine reduces cardiovascular events in high-risk patients
— Pneumococcal, COVID-19 per schedule
— Combine pills (statin + antihypertensive polypills increase adherence)
— Refill synchronization, 90-day fills, mail-order pharmacy
— Educate that statins are lifelong — stopping reverses the LDL benefit within weeks
— When FH is diagnosed, screen all first-degree relatives (parents, siblings, children) with a lipid panel — high-yield public-health Step 3 concept
Step 3 management: Document lifestyle counseling, then commit to a statin — exam answers that only offer "intensify lifestyle for another 6 months" in a high-risk patient are typically distractors.
— Recheck fasting lipid panel in 4–12 weeks to assess response and adherence
— Confirm expected LDL reduction (≥30% moderate, ≥50% high intensity)
— If response is inadequate: verify adherence first, then uptitrate, then add ezetimibe, then consider PCSK9 inhibitor (especially FH or very high risk)
— Lipid panel every 3–12 months once stable
— Routine LFT/CK monitoring not required — symptom-driven
— Annual ASCVD risk reassessment; review risk-enhancers, new diagnoses (CKD, DM)
— Reassess for ASCVD development — new chest pain, claudication, TIA → moves to secondary prevention
— Ask about muscle symptoms, fatigue, new medications (CYP3A4 inhibitors), grapefruit intake
— Pharmacy refill review; ~50% non-adherence rate at 1 year
— Statins are lifelong; benefit accrues over years
— Lifestyle plus statin > either alone
— Muscle aches are common but rarely dangerous; do not stop without calling
— Pregnancy planning → notify clinician to stop statin
— Initial: counsel, baseline labs, start statin
— 4–12 wk: response check, tolerability, titrate
— 3–6 mo: confirm stable
— Annual thereafter: lipid panel, BP, weight, glucose, lifestyle, adherence
— Not formally covered by insurance in primary prevention, but supervised exercise programs benefit high-risk patients (DM, obesity, post-bariatric)
— Refer to registered dietitian (often covered for hyperlipidemia + DM/CKD); refer to tobacco cessation programs
Board pearl: A patient on atorvastatin 40 mg for 3 months whose LDL drops only 15% → suspect non-adherence first, then consider dose increase, then add ezetimibe; do not jump straight to PCSK9 inhibitor.
— Step 3 emphasizes documenting shared decision-making before starting statins in borderline/intermediate-risk primary prevention
— Discuss absolute risk reduction (e.g., "your 10-yr risk drops from 12% to ~8%"), NNT (~50–100 over 5–10 years), and adverse effects (SAMS, new DM)
— Respect informed refusal; document discussion, offer follow-up
— Use plain-language risk visualization (icon arrays, "out of 100 patients like you")
— Cultural competence — South Asian, East Asian, and Black patients have different baseline risks and respond differently to dosing
— Duty to inform relatives: clinician should counsel the patient to share the diagnosis with first-degree relatives; in the US, clinicians cannot contact relatives directly without patient consent (HIPAA), but the public-health value is high
— Pediatric FH: parents consent for testing/treatment of minors; teen assent encouraged
— Women of childbearing age on statins must be counseled to use contraception and to stop the drug before conception or upon discovery of pregnancy
— Failure to counsel is a documented liability and patient-safety issue
— Discharge after MI/stroke: ensure high-intensity statin is on the discharge med list and confirmed at the post-discharge follow-up visit (medication reconciliation is a Joint Commission–level patient-safety metric)
— Primary-prevention statins started in hospital for incidental high LDL: communicate clearly to PCP
— Not directly applicable to hyperlipidemia, but elevated LDL + tobacco + uncontrolled DM in a commercial driver → discuss DOT physical implications
— Always run an interaction check at every new prescription — common pitfalls: clarithromycin, fluconazole, amiodarone, diltiazem with statins
— In adults ≥75 with limited life expectancy, deprescribing statins is appropriate and ethically supported; align with goals of care
Step 3 management: Before discharging a post-MI patient, explicitly reconcile the statin on the after-visit summary and confirm the patient can afford it — a high-yield patient-safety/transition-of-care answer choice.
— Clinical ASCVD → high intensity
— LDL ≥190 → high intensity
— DM age 40–75 → at least moderate intensity
— Age 40–75 with PCE ≥7.5% → moderate to high intensity
— High: atorvastatin 40–80, rosuvastatin 20–40
— Moderate: atorvastatin 10–20, rosuvastatin 5–10, simvastatin 20–40, pravastatin 40
— High intensity ≥50% LDL reduction
— Moderate intensity 30–49% LDL reduction
— FH and very-high risk: LDL <70 (or <55 per ESC)
— CAC = 0 → defer statin (with exceptions)
— CAC ≥100 or ≥75th percentile → initiate
— Family history premature ASCVD
— Persistent LDL ≥160
— Metabolic syndrome
— CKD
— Chronic inflammatory disease
— Preeclampsia, premature menopause
— South Asian ancestry
— hs-CRP ≥2, Lp(a) ≥50 mg/dL, ApoB ≥130, ABI <0.9
— Hypothyroidism → ↑LDL; treat first
— Nephrotic syndrome → ↑LDL; treat underlying
— TG >500 → fibrate or omega-3 first to prevent pancreatitis
— Pregnancy → stop statins; use bile-acid sequestrants if needed
— Gemfibrozil + statin = rhabdo; use fenofibrate
— Simvastatin >20 mg + amiodarone or amlodipine → myopathy
— Rosuvastatin max 10 mg if eGFR <30
— Dialysis: do not start statin for primary prevention
— Heterozygous 1:250; homozygous 1:300,000
— Tendon xanthomas, corneal arcus <45, premature ASCVD
— Cascade screen first-degree relatives
Board pearl: Memorize that the four statin-benefit groups + risk-enhancers + CAC form virtually every Step 3 hyperlipidemia question.
— 55-year-old man, BP 140/85 untreated, smoker, TC 220, HDL 38, non-diabetic, no ASCVD
— Calculated 10-yr risk = 13% → moderate- to high-intensity statin after shared decision-making
— Distractors: aspirin, ezetimibe, fish oil, lifestyle alone
— 35-year-old woman, LDL 215, father MI at 42, Achilles tendon xanthoma
— Answer: high-intensity statin (atorvastatin 40–80 or rosuvastatin 20–40), cascade screening relatives
— Do not waste time on the PCE
— 52-year-old with T2DM × 12 years, LDL 110, A1c 7.4, microalbuminuria
— Answer: high-intensity statin (multiple DM risk-enhancers); moderate intensity is wrong here
— 58-year-old man, 10-yr risk = 9%, no risk-enhancers, prefers not to take pills
— Best next step: order CAC; if 0 → defer, if ≥100 → start
— Bilateral thigh aches after 6 weeks on rosuvastatin 20, normal CK and TSH
— Best step: hold statin 2–4 weeks → re-challenge at lower dose or alternate statin; not "stop forever"
— TG 1400, abdominal pain, lipase elevated → admit, IV insulin, fenofibrate, glycemic control; do not start a statin first
— Woman 8 wks pregnant on atorvastatin → discontinue; counsel that lipids rise physiologically and statins are restarted postpartum (after breastfeeding)
— 78-year-old, mild dementia, life expectancy ~5 yr, never on statin
— Answer: discuss goals of care; reasonable to defer; do not auto-prescribe
— Patient on simvastatin 40 mg started on clarithromycin → hold simvastatin during course
— Best add-on: ezetimibe, then bempedoic acid or PCSK9 inhibitor
Key distinction: Step 3 stems usually hinge on a single decision — what is the next best step today — pick the most concrete action (start drug, order CAC, hold drug, counsel) rather than vague observation.
For primary prevention of ASCVD, calculate 10-year risk with the Pooled Cohort Equation in adults 40–75, then initiate a moderate- to high-intensity statin in any patient with clinical ASCVD, LDL ≥190, diabetes age 40–75, or 10-yr risk ≥7.5% — refining borderline/intermediate cases with risk-enhancers and coronary artery calcium scoring, all anchored in lifestyle therapy and shared decision-making.
Board pearl: The single most common Step 3 trap is treating elevated LDL without first ruling out secondary causes (TSH, urinalysis, A1c, LFTs) and without confirming the panel — repeat and rule out before committing a patient to lifelong therapy.